Summary
Metabolites of dipyrone have been determined in the saliva of 18 volunteers following the oral intake of 0.5 g, 1.0 g, 1.5 g, 2.0 g and 2.5 g dipyrone. High concentrations were measured for N-methyl-aminoantipyrine (MAA), the other analgetic active metabolite, 4-aminoantipyrine was found in minor quantities only. N-formyl-antipyrine was not present in the saliva of some volunteers after low doses but could be determined following the intake of doses from 1.5 g – 2.5 g in saliva of all volunteers. N-acetyl-antipyrine appears late in saliva, acetylation rates varied greatly interindividually. Concentrations of the metabolites in saliva mimic the respective non-protein bound fraction in plasma found by other authors. Send reprint request to: Prof. Dr. P. Rohdewald, Institut für Pharmazeutische Chemie der Westfälischen Wilhelms-Universität Münster, Hittorfstr. 58/62, D-4400 Münster (FRG).
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Badian M., Brockmeier D., Dagrosa E.E., Grigoleit H.G., Grötsch H., Hajdu P., Lefevre G., Reifenberger D., Rupp W., Usinger P., Blahov V. (1987): Pharmacokinetic profile of dipyrone for different doses and multiple dosing. Pain Supplement4, S47.
Brown R.D., Manno J.E. (1978): ESTRIP, a BASIC computer program for obtaining initial polyexponential parameters estimates. J. Pharm. Sci.67, 1687–1691.
Brune K., Alpermann H. (1983): Nonacidic pyrazoles: Inhibition of prostaglandin production, carrageenan edema and yeast fever. Agents and actions13, 360–363.
Danhof M., Breimer D.D. (1978): Therapeutic drug monitoring in saliva. Clin Pharmacokinet3, 39–57.
Iguchi S., Goromaru T., Nöda A. (1975): A new metabolite of aminopyrine (aminophenazone) in man, 4-formylaminoantipyrine. Chem. Pharm. Bull.23, 932–934.
Levy M. (1985): Pharmakokinetik von Metamizolmetaboliten. in: 100 Jahre Pyrazolone, Urban and Schwarzenberg, München Wien Baltimore, p. 163-166.
Levy M., Flusser D., Zylber-Katz E., Granit L. (1984): Plasma kinetics of dipyrone metabolites in rapid and slow acetylators. Eur. J. Clin. Pharmacol.27, 453–458.
Rohdewald P., Derendorf H., Drehsen G., Elger CE., Knoll O. (1982): Changes in cortical evoked potentials as correlates of the efficacy of weak analgesics. Pain12, 329–341.
Rohdewald P., Derendorf H., Drehsen G., Granitzki H.W., Neddermann E. (1985): Die Dämpfung des experimentell induzierten Schmerzes durch Pyrazolone. In: 100. Jahre Pyrazolone, Urban and Schwarzenberg, Münohen Wien Baltimore, p. 61-67.
Rohdewald P., Drehsen G., Milsmann E., Derendorf H. (1983): Relationship between saliva levels of metamizolmetabolites, bioavailability and analgesic efficacy. Arzneimittelforschung (Drug Research)33, 985–988.
Rohdewald P., Neddermann E. (1988): Dosisabhängigkeit der analgetischen Wirkung von Metamizol. Anaesthesist (in press).
fnVolz M., Kellner H.M. (1980): Kinetics and metabolism of pyrazolones (propyphenazone, aminopyrine and dipyrone). Br. J. Clin. Pharmacol. pp299S-308S.
Weiss R., Brauer J., Goertz U., Petry R. (1974): Vergleichende Untersuchungen zur Frage der Absorption und Metabolisierung des Pyrazolonderivates Metamizol nach oraler und intramuskulärer Gabe beim Menschen. Arzneimittelforsch24, 345–348.
Weithmann K.U., Alpermann H.G. (1985): Biochemical and pharmacological effects of dipyrone and its metabolites in model systems related to arachidonic acid cascade. Arzneimittelforschung (Drug Research)35, 947–952.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Neddermann, E., Rohdewald, P. Dose-dependent pharmacokinetics of metabolites of dipyrone in saliva. European Journal of Drug Metabolism and Pharmacokinetics 13, 105–111 (1988). https://doi.org/10.1007/BF03191311
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF03191311